Navigation Links
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:2/25/2008

MOUNTAIN VIEW, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has initiated its first Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. Alexza believes the novel, non-invasive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a viable product to treat acute agitation. AZ-004 is being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital, LLC.

"We are excited to be initiating our AZ-004 NDA plan with this first Phase 3 clinical trial," said Thomas B. King, Alexza President and CEO. "The results we have seen to date with AZ-004 have been promising and we look forward to enrolling the planned Phase 3 clinical trials as quickly as possible. This is a transitional year in our history as we move into the early commercial planning for the manufacturing, regulatory submissions, and potential sales and marketing of AZ-004."

AZ-004 Phase 3 Clinical Trial Design

The first AZ-004 Phase 3 clinical trial is designed to enroll approximately 300 schizophrenic patients with acute agitation at 25 U.S. clinical centers. The trial is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study and will test AZ-004 at two dose levels, 5 and 10 mg. Patients may receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status.

The primary endpoint for the study is the change from baseline in the PANSS (Positive and
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 METTLER TOLEDO’s newly improved XS ... balances as well as a dual range ... the new SmartPan™ weighing pan delivers results up to ... all balances, ergonomic design details mean users no longer ... for long periods in front of the balance. Barbara ...
(Date:10/1/2014)... 1, 2014 Pfanstiehl has announced the ... manufactured in the USA ... been recognized for playing a key role in ... of evidence that media supplementation with mannose can ... glycosylation," according to Dr. Christopher Wilcox , ...
(Date:10/1/2014)... 30, 2014 New applications of structures ... have evolved in nature over millennia are featured in ... for applications in biophotonics in the October issue ... journal is published by SPIE, the international society for ... of the peer-reviewed articles are accessible via open access. ...
(Date:10/1/2014)... This report analyzes the worldwide ... by the following Product Segments: Proteases, Polymerases, ... segments also analyzed are Pharmaceuticals & Diagnostics, ... provides separate comprehensive analytics for the US, ... Latin America. Annual estimates and forecasts are ...
Breaking Biology Technology:METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26
... TRBN ) announced today that its collaboration ... WYE ), has initiated a Phase 1 clinical ... for the treatment of systemic lupus erythematosus (SLE). Based ... also being evaluated in a Phase 1 clinical trial ...
... an economic environment where many healthcare providers are ... patients are thriving with help from InstaMed. ... and platform, Prime Health Network has increased patient ... while also improving the patient experience at each ...
... Cynvec LLC, a privately held biotechnology company focused on ... of the sindbis viral vector, today announced that Frank ... the BIO National Venture Conference in Boston on Wednesday, ... About Cynvec LLC , Cynvec, a privately held ...
Cached Biology Technology:Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 2Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 3Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 2Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 3
(Date:9/30/2014)... environmental scientists and engineers, led by Clemson University ... $5.25 million grant from the U.S. Department of ... make a direct positive impact on South Carolina ... of radioactive contaminants. , "Understanding the scientific and ... environmental aspects of nuclear technologies is imperative if ...
(Date:9/30/2014)... farm runoff in Hawaii is causing tumors in endangered ... study, published Tuesday in the peer-reviewed open-access journal ... up in algae that the turtles eat, promoting the ... internal organs. , Scientists at Duke University, the University ... (NOAA) conducted the study to better understand the causes ...
(Date:9/30/2014)... is available in German . ... behavioural response to risky situations such as exposure to ... now found in a long-term study on different populations ... metabolic rate and ambient temperature. High metabolic rates and ... in these scenarios birds were more likely to approach ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... PA, September 17, 2007 Women and men appear ... Major depressive disorder (MDD) is one of the most ... the most studied. It is already known that ... changes, associated with MDD and most of todays most ...
... (ACS) News Service Weekly press package (PressPac) with reports ... Engineering News. With more than 160,000 members, ACS is ... journal, or the American Chemical Society, as the source ... ARTICLE #1 FOR IMMEDIATE RELEASE New ...
... Nature Genetics on Sunday 16 September 2007 show that common, ... variation in regions that control activity of genes, rather than ... surprising result comes from a study at the Wellcome Trust ... 270 DNA samples collected for the HapMap Project. The authors ...
Cached Biology News:Women more depressed and men more impulsive with reduced serotonin functioning 2American Chemical Society's Weekly PressPac -- Sept. 12, 2007 2American Chemical Society's Weekly PressPac -- Sept. 12, 2007 3American Chemical Society's Weekly PressPac -- Sept. 12, 2007 4American Chemical Society's Weekly PressPac -- Sept. 12, 2007 5American Chemical Society's Weekly PressPac -- Sept. 12, 2007 6American Chemical Society's Weekly PressPac -- Sept. 12, 2007 7American Chemical Society's Weekly PressPac -- Sept. 12, 2007 8The importance of gene regulation for common human disease 2
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
Biology Products: